These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1888 related articles for article (PubMed ID: 31369120)

  • 1. Cyclin-dependent kinase 4/6 inhibitors for the management of advanced or metastatic breast cancer in women.
    Cersosimo RJ
    Am J Health Syst Pharm; 2019 Aug; 76(16):1183-1202. PubMed ID: 31369120
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Role of cyclin-dependent kinase 4/6 inhibitors in the current and future eras of cancer treatment.
    Parylo S; Vennepureddy A; Dhar V; Patibandla P; Sokoloff A
    J Oncol Pharm Pract; 2019 Jan; 25(1):110-129. PubMed ID: 29726787
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical Management of Potential Toxicities and Drug Interactions Related to Cyclin-Dependent Kinase 4/6 Inhibitors in Breast Cancer: Practical Considerations and Recommendations.
    Spring LM; Zangardi ML; Moy B; Bardia A
    Oncologist; 2017 Sep; 22(9):1039-1048. PubMed ID: 28706010
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of treatment-related adverse events of different Cyclin-dependent kinase 4/6 inhibitors in metastatic breast cancer: A network meta-analysis.
    Desnoyers A; Nadler MB; Kumar V; Saleh R; Amir E
    Cancer Treat Rev; 2020 Nov; 90():102086. PubMed ID: 32861975
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Differences of cyclin-dependent kinase 4/6 inhibitor, palbociclib and abemaciclib, in breast cancer.
    Tamura K
    Jpn J Clin Oncol; 2019 Dec; 49(11):993-998. PubMed ID: 31665472
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Palbociclib Combined with Fulvestrant in Premenopausal Women with Advanced Breast Cancer and Prior Progression on Endocrine Therapy: PALOMA-3 Results.
    Loibl S; Turner NC; Ro J; Cristofanilli M; Iwata H; Im SA; Masuda N; Loi S; André F; Harbeck N; Verma S; Folkerd E; Puyana Theall K; Hoffman J; Zhang K; Bartlett CH; Dowsett M
    Oncologist; 2017 Sep; 22(9):1028-1038. PubMed ID: 28652278
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cyclin-dependent kinase 4/6 inhibitors as first-line treatment for post-menopausal metastatic hormone receptor-positive breast cancer patients: a systematic review and meta-analysis of phase III randomized clinical trials.
    Ramos-Esquivel A; Hernández-Steller H; Savard MF; Landaverde DU
    Breast Cancer; 2018 Jul; 25(4):479-488. PubMed ID: 29470723
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cyclin-dependent kinase 4/6 inhibitors in breast cancer: palbociclib, ribociclib, and abemaciclib.
    Kwapisz D
    Breast Cancer Res Treat; 2017 Nov; 166(1):41-54. PubMed ID: 28741274
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A current and comprehensive review of cyclin-dependent kinase inhibitors for the treatment of metastatic breast cancer.
    Bilgin B; Sendur MAN; Şener Dede D; Akıncı MB; Yalçın B
    Curr Med Res Opin; 2017 Sep; 33(9):1559-1569. PubMed ID: 28657360
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Review of Cyclin-Dependent Kinase 4/6 Inhibitors for the Treatment of Hormone Receptor-Positive Advanced Breast Cancer.
    Hecht KA; Selby C
    Ann Pharmacother; 2019 Feb; 53(2):195-203. PubMed ID: 30079740
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CDK4/6 Inhibitors Expand the Therapeutic Options in Breast Cancer: Palbociclib, Ribociclib and Abemaciclib.
    Eggersmann TK; Degenhardt T; Gluz O; Wuerstlein R; Harbeck N
    BioDrugs; 2019 Apr; 33(2):125-135. PubMed ID: 30847853
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeting CDK4/6 pathways and beyond in breast cancer.
    Ribnikar D; Volovat SR; Cardoso F
    Breast; 2019 Feb; 43():8-17. PubMed ID: 30359883
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CDK4/6 Inhibition as a therapeutic strategy in breast cancer: palbociclib, ribociclib, and abemaciclib.
    Laderian B; Fojo T
    Semin Oncol; 2017 Dec; 44(6):395-403. PubMed ID: 29935901
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Growing Role of CDK4/6 Inhibitors in Treating Hormone Receptor-Positive Advanced Breast Cancer.
    Shah AN; Cristofanilli M
    Curr Treat Options Oncol; 2017 Jan; 18(1):6. PubMed ID: 28197838
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Resistance to cyclin-dependent kinase (CDK) 4/6 inhibitors confers cross-resistance to other CDK inhibitors but not to chemotherapeutic agents in breast cancer cells.
    Ogata R; Kishino E; Saitoh W; Koike Y; Kurebayashi J
    Breast Cancer; 2021 Jan; 28(1):206-215. PubMed ID: 32860163
    [TBL] [Abstract][Full Text] [Related]  

  • 16. HR+, HER2- Advanced Breast Cancer and CDK4/6 Inhibitors: Mode of Action, Clinical Activity, and Safety Profiles.
    Sammons SL; Topping DL; Blackwell KL
    Curr Cancer Drug Targets; 2017; 17(7):637-649. PubMed ID: 28359238
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cyclin-dependent kinase 4/6 inhibitors in hormone receptor-positive early breast cancer: preliminary results and ongoing studies.
    Kwapisz D
    Breast Cancer; 2018 Sep; 25(5):506-516. PubMed ID: 29700711
    [TBL] [Abstract][Full Text] [Related]  

  • 18. PACE: A Randomized Phase II Study of Fulvestrant, Palbociclib, and Avelumab After Progression on Cyclin-Dependent Kinase 4/6 Inhibitor and Aromatase Inhibitor for Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor-Negative Metastatic Breast Cancer.
    Mayer EL; Ren Y; Wagle N; Mahtani R; Ma C; DeMichele A; Cristofanilli M; Meisel J; Miller KD; Abdou Y; Riley EC; Qamar R; Sharma P; Reid S; Sinclair N; Faggen M; Block CC; Ko N; Partridge AH; Chen WY; DeMeo M; Attaya V; Okpoebo A; Alberti J; Liu Y; Gauthier E; Burstein HJ; Regan MM; Tolaney SM
    J Clin Oncol; 2024 Jun; 42(17):2050-2060. PubMed ID: 38513188
    [TBL] [Abstract][Full Text] [Related]  

  • 19. An Update on the Clinical Use of CDK4/6 Inhibitors in Breast Cancer.
    Robert M; Frenel JS; Bourbouloux E; Rigaud DB; Patsouris A; Augereau P; Gourmelon C; Campone M
    Drugs; 2018 Sep; 78(13):1353-1362. PubMed ID: 30143968
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Why upfront use of CDK inhibitors for the treatment of advanced breast cancer may be wasteful, and how we can increase their value.
    Niraula S
    Breast; 2019 Feb; 43():81-84. PubMed ID: 30513476
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 95.